Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.

Microbial drug resistance (Larchmont, N.Y.) - 1 Dec 2009

Mendes Rodrigo E, Jones Ronald N, Deshpande Lalitagauri M, Ross James E, Sader Hélio S

Abstract excerpt

Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus spp. represent the most frequently recovered organisms from bloodstream infections. As a treatment option, daptomycin has been recently approved for the treatment of S. aureus bacteremia and right-sided endocarditis. We eva...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Daptomycin
Share to Enterococcus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Linezolid

Share to Oxazolidinones

Share to RNA, Bacterial

Share to RNA, Ribosomal, 23S

Share to Staphylococcus

Source

Identifiers

PMID: 19857129
DOI: 10.1089/mdr.2009.0045

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19857129-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.PMID 19857129Read ↗

Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015)Semantic proximity Read ↗

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.Semantic proximity Read ↗

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.Semantic proximity Read ↗

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).Semantic proximity Read ↗

Mechanisms of drug resistance: daptomycin resistance.Semantic proximity Read ↗

ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countriesSemantic proximity Read ↗

Linezolid: a review of its properties, function, and use in critical care.Semantic proximity Read ↗

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Semantic proximity Read ↗

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive OrganismsSemantic proximity Read ↗

Genetic profile of MRSA and MSSA clinical isolates with daptomycin MIC > 1 mg/LSemantic proximity Read ↗

Whole-genome sequencing identifies MprF mutations in a genetically diverse population of daptomycin non-susceptible Staphylococcus aureus in Australia.Semantic proximity Read ↗

Daptomycin Resistant Staphylococcus aureus Clinical Strain With Novel Non-synonymous Mutations in the mprF and vraS Genes: A New Insight Into Daptomycin ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.